Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Intarcia Therapeutics clinical trials
Also known as BioMedicines.
The registry lists 22 studies whose lead sponsor is Intarcia Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 7, 2019.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Intarcia Therapeutics.
- Intarcia Therapeutics21 studiesSame company
Something wrong?
- BioMedicines1 studySame company
Something wrong?
Focus areas
Conditions Intarcia Therapeutics leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminTerminatedNCT03060980Phase 3
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1cTerminatedNCT01785771Phase 3
- Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving LiraglutideCompletedNCT02638805Phase 3
- A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650CompletedNCT01455896Phase 3
- Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied DrugsCompletedNCT02641899Phase 1
- Study of the Effects of Intravenous Exenatide on Cardiac RepolarizationCompletedNCT02650479Phase 1
- Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal SubjectsCompletedNCT02320045Phase 1
- A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 DiabetesCompletedNCT01455870Phase 3
- Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female SubjectsCompletedNCT02641990Phase 1
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 DiabetesCompletedNCT01455857Phase 3
- Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerCompletedNCT00044291Phase 3
- Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes MellitusCompletedNCT00943917Phase 2
- Toremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast CancerTerminatedNCT00010322Phase 3
- Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 DiabetesCompletedNCT01798264Phase 1
- Biomed 101 and Interleukin-2 in Treating Patients With Kidney CancerCompletedNCT00004890Phase 1
Sponsor listed in the registry: BioMedicines
- A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 DiabetesWithdrawnNCT01455922Phase 3
- A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 DiabetesWithdrawnNCT01455909Phase 3
- A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 DiabetesWithdrawnNCT01455883Phase 3
- Phase 1b Study of Omega DUROS® in Patients With Chronic Hepatitis C Who Relapsed After Prior TreatmentCompletedNCT00519792Phase 1
- Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast CancerTerminatedNCT00267553Phase 3
- The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast CancerTerminatedNCT00097344Phase 3
- Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis CCompletedNCT00097045Phase 2